Pay in 4 interest-free payments of $6.25 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
We think current share prices do not properly account for expected price declines and competition, let alone the risk of patients discontinuing therapy due to tolerability, cost, or long-term safety issues, says Karen Andersen, healthcare strategist at Morningstar
More companies are likely to introduce competing products, the manufacturers are offering lower prices direct-to-consumer (DTC), and compounded medications with lower prices continue to be available
In its lawsuit, the OFA said that the FDAs decision to end the shortage was a reckless and arbitrary move and could deprive patients of a vital treatment for type 2 diabetes and obesity. In an interview with BioSpace last month, David Rosen, partner at Foley & Lardner, said that the lawsuit is a precedent in this area. Prior to the OFA suit, no one has ever challenged the FDAs decision to remove a therapy from the drug shortage list. The OFA case is still ongoing, with the next court update due on Thursday
doi:10.1056/NEJMoa2032183 Lempesis IG, Liu J, Dalamaga M
US$ 22.07
US$ 22.52
US$ 23.62
US$ 29.92
US$ 20.11
US$ 22.74
US$ 22.52
US$ 28.42
US$ 29.65
US$ 23.33
